Survivin inhibitor is a class of pharmaceutical compounds designed to target and inhibit the survivin protein, which plays a crucial role in regulating apoptosis (programmed cell death) and promoting cell survival. By blocking survivin, these inhibitors aim to induce apoptosis in cancer cells, hindering tumor growth and potentially improving cancer treatment outcomes. Survivin inhibitors have been primarily investigated for their potential in various cancer types, including breast, lung, colon, ovarian, and prostate cancers, where survivin is frequently overexpressed. According to the World Health Organization (WHO), cancer remains a significant health challenge in Europe and the USA, with millions of new cases reported annually. Breast cancer is one of the most common malignancies, affecting approximately 2.1 million women each year worldwide, as per WHO statistics. Lung cancer also poses a substantial burden, with over 2.2 million new cases worldwide, and colorectal cancer accounts for nearly 1.8 million cases annually. Ovarian cancer affects around 313,000 women globally, while prostate cancer remains a significant concern for men, with over 1.4 million new cases reported annually.
Growth drivers for the Survivin inhibitor market include promising clinical trial results, demonstrating their efficacy in specific cancer types, along with the increasing adoption of personalized medicine and targeted therapies. Companies such as Marker Therap, AbbVie, Astellas, Cothera Biosci, EMD Serono, Eli Lilly, Enzon, and Erimos are pharmaceutical companies operating in the healthcare industry. cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, Cothera Bioscience is currently conducting a clinical trial of the drug PC-002 for the treatment of lymphoma.
Key Developments
- In Feb 2023, IMV released safety and efficacy data from a phase IIb VITALIZE trial of Maveropepimut in diffuse large B cell lymphoma.
- In Dec 2022, MimiVax released final efficacy and adverse event data from a phase II trial of SVN 5367 in Glioblastoma.
Approved Survivin Inhibitor Molecules
- CINelim (terameprocol)
- MultiTAA T cell therapy
Survivin Inhibitor Pipeline Molecules
- maveropepimut-S (MVP-S)
- sepantronium bromide (PC-002)
- gataparsen (LY2181308)
- IO101
- MT-601
- SL-701
- ABBV-184
- MANA-312
- NEXI-003
Clinical Activity and Development of Survivin Inhibitor
In the Survivin Inhibitor space, there are very few companies, conducting more than more than 50 clinical trials in this category of drugs. For instance,
- In April 2023, IMV presented efficacy data from a phase I/II DeCidE1 trial of Maveropepimut S in Ovarian cancer at the 114th Annual Meeting of the American Association for Cancer Research, 2023 (AACR-2023)
- In May 2022, Astellas pharma presented pharmacodynamics data from a preclinical trial of Sepantronium bromide in renal cell carcinoma at the 117th annual meeting of the American Urological Association
|
Product Name |
Total Studies |
|
maveropepimut-S (MVP-S) |
14 |
|
sepantronium bromide (PC-002) |
12 |
|
gataparsen (LY2181308) |
4 |
|
IO101 |
2 |
Target Indication Analysis of Survivin Inhibitor
Survivin inhibitors are targeted therapeutic agents designed to block the activity of the survivin protein, which is overexpressed in various cancer types, including breast, lung, colon, and ovarian cancers. By inhibiting survivin, these drugs aim to induce apoptosis (programmed cell death) in cancer cells, thereby hindering tumor growth and promoting cancer cell death. The goal of survivin inhibitors is to offer a promising and potentially more selective approach to cancer treatment, with the hope of improving patient outcomes and providing a new avenue for combating the devastating impact of cancer on individuals worldwide.
Survivin Inhibitor Market Regional Analysis
Survivin Inhibitor Market
The global Survivin Inhibitor market is segmented into the United States, United Kingdom, Germany, Spain, France, Italy, and Japan. The US market for Survivin inhibitors in the pharmaceutical sector has witnessed steady growth in recent years. The increasing prevalence of various cancers, where Survivin is overexpressed, has driven the demand for these targeted therapies. Moreover, the robust healthcare infrastructure and substantial investments in research and development have contributed to the market's expansion. The presence of key pharmaceutical companies in the region has further bolstered the availability and accessibility of Survivin inhibitors. However, stringent regulatory requirements and potential competition from alternative cancer therapies remain significant challenges to be addressed for sustained market growth. The Survivin inhibitor market is poised for continued growth due to its potential as a novel and targeted approach to cancer treatment. Key drivers include promising clinical trial results demonstrating the efficacy of Survivin inhibitors in specific cancer types, leading to increased adoption by healthcare providers. Canada, on the other hand, is known for its well-established healthcare system and supportive regulatory framework, making it an attractive market for Survivin Inhibitors. These countries are increasingly adopting Survivin Inhibitors due to their efficacy and potential to improve patient outcomes. On the other hand, the Survivin Inhibitor market in Europe has witnessed significant growth in recent years. Major countries driving this market include Germany, France, Italy, and Spain. These countries have a robust pharmaceutical industry, which is a key driver for the Survivin Inhibitor market.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Frequently Asked Questions
Survivin inhibitors drugs are used in the management of various cancer types, including breast, lung, colon, and ovarian cancers.
The Survivin inhibitor market is poised for continued growth due to its potential as a novel and targeted approach to cancer treatment. Key drivers include promising clinical trial results demonstrating the efficacy of Survivin inhibitors in specific cancer types, leading to increased adoption by healthcare providers.
The major players in this space are Marker Therap, AbbVie, Astellas, Cothera Biosci, EMD Serono, Eli Lilly, Enzon, and Erimos are pharmaceutical companies operating in the healthcare industry.
The survivin inhibitor market faces significant challenges due to limited clinical success and potential adverse effects associated with targeting survivin, a protein involved in apoptosis regulation. Additionally, the development of effective and safe survivin inhibitors has been impeded by the complex biological functions of survivin, making it difficult to achieve selective inhibition without impacting normal cellular processes.
- Marker Therap
- AbbVie
- Astellas
- Cothera Biosci
- EMD Serono
- Eli Lilly
- Enzon
- Erimos Pharma
- Fosun Pharma
- IMV Inc
- IO Biotech
- Ionis
- MANA Therap
- Menarini
- MimiVax
- NexImmune
- PDC line Pharma